Key Takeaways
- The healthcare ETF market offers varied options, catering to different risk tolerances and investment goals.
- Traditional pharmaceutical funds emphasize stability and income, while biotech funds focus on high-risk, high-reward opportunities.
- Investors should consider portfolio overlap and alignment with their financial goals when selecting healthcare ETFs.
Evaluating Healthcare ETFs
For investors eyeing the healthcare sector, the breadth of exchange-traded funds (ETFs) can be overwhelming. Recent analyses from The Motley Fool compare popular healthcare ETFs, revealing a divide between traditional pharmaceutical stocks that offer steady dividends and the more volatile biotechnology sector promising explosive growth potential. The deciding factors often hinge on an investor’s timeline, risk tolerance, and need for income.
Stable Pharma ETFs: XLV, IYH, and IHE
On the defensive side, the State Street Health Care Select Sector SPDR ETF (XLV) provides exposure to 60 leading U.S. healthcare firms, boasting over $41.7 billion in assets. With major holdings like Eli Lilly (16.39%) and Johnson & Johnson (10.80%), XLV has achieved a total return of 864% since 1998, with a compound annual growth rate (CAGR) of 8.6%, close to the S&P 500’s 8.8%. It also presents an expense ratio of 0.08% and a trailing dividend yield of 1.60%.
The iShares U.S. Healthcare ETF (IYH) has 100 holdings, with its top five stocks comprising roughly 45% of total exposure. Although it has produced a 10-year total return of 153% (CAGR of 9.7%), it falls short compared to the S&P 500’s 317%. IYH carries an expense ratio of 0.38% and yields 1.20%.
Meanwhile, the iShares U.S. Pharmaceuticals ETF (IHE) focuses on 56 stocks, with major positions in Johnson & Johnson and Eli Lilly, which together comprise over 44% of assets. It boasts a higher dividend yield of 2.16% and lower volatility, with a five-year beta of 0.63, and an expense ratio of 0.38%.
High-Risk Biotech ETFs: IBBQ, BBH, and IBB
Contrasting the stable options are biotech funds designed for risk-tolerant investors. The Invesco Nasdaq Biotechnology ETF (IBBQ), with 253 stocks, trades under a high degree of volatility. Since its 2021 launch, it has returned 35% with an expense ratio of 0.19% and a minimal yield of 0.80%.
The VanEck Biotech ETF (BBH), more concentrated with 25 companies, has achieved a total return of 98% since 2016, despite trailing IYH’s performance. Its expense ratio sits at 0.35%, and it offers a yield of just 0.50%.
Lastly, the iShares Biotechnology ETF (IBB) holds 248 companies and, with an expense ratio of 0.44%, represents the high-risk nature of the biotech industry, as firms often allocate funds back to research rather than dividends.
Portfolio Considerations
Choosing among these funds goes beyond sector bets; it can significantly influence portfolio construction. Notably, funds like IHE and IBB may overexpose investors to heavyweight stocks also found in broader indexes. Investors should weigh these overlaps against their financial objectives, whether aiming for stability with funds like XLV or chasing growth with IBBQ. Blending strategies can blend defensive and aggressive investments for a balanced approach.
The content above is a summary. For more details, see the source article.